sur VVardis AG
VVardis Secures Apollo Investment, Achieves Unicorn Status
On April 27, 2026, vVardis Holding AG, a Swiss dental medtech company, announced a strategic investment from Apollo-managed funds. This investment supports the expansion of their non-invasive Curodont™ technology, which treats tooth decay without drilling. vVardis now ranks among Europe's top healthcare unicorns.
Founded by Drs. Haley and Goly Abivardi, vVardis is revolutionizing cavity treatment. Since its U.S. launch, Curodont™ has been implemented in 20% of dental practices, treating around 3 million teeth. The firm plans further expansion in the U.S. and Europe, backed by clinical studies validating their innovative approach.
The investment from Apollo strengthens vVardis' market presence, allowing it to broaden its reach and sustain its growth across key markets. The terms of the deal remain undisclosed, but the investment is key to advancing vVardis' mission of offering non-invasive dental solutions.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de VVardis AG